ArticleJournal of hepatocellular carcinoma2026
Sequential Multimodal Therapy for Conversion Resection of Stage IIIa Hepatocellular Carcinoma: A Case Report.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the feasibility and clinical value of conversion resection after sequential comprehensive therapy consisting of transarterial chemoembolization (TACE), targeted therapy, immunotherapy and radiotherapy in patients with initially advanced stage IIIa hepatocellular carcinoma (HCC). Methods: The clinical data of a 61-year-old male patient with massive stage IIIa HCC accompanied by right portal vein tumor thrombus were retrospectively analyzed. The maximum diameter of the primary tumor was approximately 10.0 cm at initial diagnosis. The patient received sequential combination therapy of TACE plus targeted-immunotherapy for 8 months, followed by liver tumor radiotherapy about 1 month and maintenance targeted-immunotherapy for 12 months. After sustained tumor shrinkage, radical resection was performed on March 13, 2026. Results: Following sequential multimodal treatment, the maximum tumor diameter decreased from 10.0 cm to 4.0 cm × 3.6 cm, achieving partial response (PR). The tumor was successfully downstaged to resectable status, and the patient recovered smoothly postoperatively without severe complications. Conclusion: Sequential comprehensive therapy combining TACE, targeted-immunotherapy and radiotherapy can significantly downstage initially advanced stage IIIa HCC, create opportunities for curative resection, and potentially improve long-term prognosis of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.